Bacteriological analysis of bile in acute cholecystitis according to the Tokyo guidelines

J Hepatobiliary Pancreat Sci. 2012 Jul;19(4):476-86. doi: 10.1007/s00534-011-0463-9.

Abstract

Background: We performed bacteriological analysis of bile in acute cholecystitis (AC) patients graded in severity according to the Tokyo guidelines.

Methods: We enrolled 163 AC patients in whom bacteriological analysis of bile was performed.

Results: Significant differences in age (60 vs. 67 years), body temperature (BT) (37.2 vs. 37.6°C), white blood cell count (13,033 vs. 15,177/mm(3)), and serum C-reactive protein (CRP) (8.9 vs. 16.9 mg/dL) were found between the Mild and Moderate severity groups. The prevalence of bactibilia differed significantly between Mild and Moderate patients (45.3 vs. 67.0%, P = 0.0107); however, there were no significant differences in the bacterial strains, prevalence of antimicrobial resistance, or polymicrobial isolation frequency between the 2 groups. Our local antibiogram revealed that several microorganisms showed higher resistance rates; these were also isolated even in Mild cases. Advanced age, high BT, high serum CRP, and presence of marked local infection were identified as being significantly associated with high risk of bactibilia. Receiver operating characteristic curve analysis indicated the optimal cutoff value of age to be 65 years, of BT to be 37.5°C, and of serum CRP to be 13.4 mg/dL.

Conclusion: Adequate broad-spectrum antimicrobial therapy should be administered perioperatively even for Mild patients classified according to the current Tokyo guidelines. These results suggest that more precise severity grades may need to be established, including age and CRP as additional parameters.

MeSH terms

  • Adult
  • Aged
  • Aged, 80 and over
  • Bile / microbiology*
  • C-Reactive Protein / analysis
  • Cholecystitis, Acute / microbiology*
  • Female
  • Humans
  • Male
  • Middle Aged
  • ROC Curve
  • Sensitivity and Specificity
  • Severity of Illness Index

Substances

  • C-Reactive Protein